Skip to content
‹ Back to IndustriesHealthcare

Improving Brain Tumor Segmentation at the Edge

Intel’s Abhishek Khowala, principal health AI engineer, and Séverine Habert, AI engineering manager, discuss some of the enhancements in brain tumor segmentation for enabling diagnosis. While most brain tumors are benign, early detection is critical for the best treatment options and outcomes. Assessing a diagnosis starts with MRI 2D and 3D imaging. Segmentation of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Intel’s Abhishek Khowala, principal health AI engineer, and Séverine Habert, AI engineering manager, discuss some of the enhancements in brain tumor segmentation for enabling diagnosis.

While most brain tumors are benign, early detection is critical for the best treatment options and outcomes. Assessing a diagnosis starts with MRI 2D and 3D imaging. Segmentation of the brain tumor – or separating the tumor from normal brain tissues – is essential to identifying three key factors to allow doctors to move forward:

  1. Is the tumor benign or malignant?
  2. The approximate tumor size and location.
  3. Plan out the treatment options.

“We need to segment out the tumor from the rest of the tissues around it,” Khowala says. “For that, there is the unit model. And that architecture works with fewer amounts of data yet provides a clearer segmentation result.”

The brain tumor segmentation (BraTS) combined with OpenVINO™ toolkit could optimize MRI results during tumor detection and monitoring. “Since this is something that has to happen worldwide, we need to deploy it at scale,” Khowala explains. Scaling requires overcoming a few challenges. Utilizing OpenVINO erases issues of high-cost GPU required for deploying AI solutions or perceived performance limitations of common frameworks such as PyTorch or TensorFlow. “Brain tumor segmentation is a perfect example of applying the most common architecture and using it for multiple devices from edge to handheld devices,” Habert adds.

For optimized AI, the provided data must be robust, which is not an easy task. According to Khowala, Expert radiologists are required to interpret the MRI images to get to the ground truth data. BraTS helps predict results and compare accuracy with provided ground truth results using the Sørensen–Dice coefficient datasets. Once the data is available, modeling can take place and assist medical professionals in their diagnosis.

Learn more about brain tumor segmentation solutions by connecting with Abhishek Khowala and Séverine Habert on LinkedIn or visit:

https://www.intel.com/content/www/us/en/healthcare-it/healthcare-overview.html.

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Harbor Health to buy 27 Village Medical clinics in Greater Houston

Harbor Health to buy 27 Village Medical clinics in Greater Houston

Harbor Health's purchase of Village Medical clinics in Houston is expected to close at the end of 2026. The 27 clinics are the primary care home for Harbor members in four counties.

  • 01Harbor's $0 specialist benefit only applies when a Harbor clinician makes the referral. For Houston employers, the test is whether employees will use the 27 clinics as their first stop.

Oct 8, 2026

SCI recruits funeral sales as the career AI cannot replace

SCI recruits funeral sales as the career AI cannot replace

SCI's recruiting video positions funeral and cremation sales as a career resistant to automation by emphasizing the human trust required in end-of-life planning. The pitch frames the role as requiring both compassion and sales drive, targets people outside the industry, and leans on demographic demand from an aging population to argue for job stability.

  • 01More than 11,000 Americans turn 65 daily, SCI says demand will grow.
  • 02SCI seeks candidates with dual traits: compassion and empathy alongside sales-oriented drive and tenacity.
  • 03The role requires no prior industry experience; SCI provides training, coaching, and technology to prepare newcomers.

Oct 7, 2026

CURORI Details Readiness Framework for Planned Ten-City Expansion in China

CURORI, a China-based medical-aesthetic coordination platform founded in 2025, has outlined a readiness framework to expand its city coverage from five to ten Chinese destinations by the end of 2027. The expansion will be phased around provider and service readiness rather than destination count alone, with review areas including qualified doctors, licensed institutions, procedure categories, communication processes, and practical factors for international users.

  • 01CURORI plans to expand from five currently served cities (Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou) to ten by December 31, 2027, with Chengdu, Xi'an, Wuhan, and two additional locations under evaluation.
  • 02The company's readiness framework requires operational checks across provider qualifications, licensed institutions, procedure availability, assessment requirements, communication processes, quotation clarity, appointment coordination, and follow-up arrangements before launching in new cities.
  • 03CURORI has a separate objective to help reduce client costs by approximately 10% by the end of 2026 through comparison, clearer quotation information, free initial coordination, and future incentives.

Oct 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512